Duration of Aspirin and Cilostazol for TIA and Ischemic Stroke
Long-term antiplatelet therapy should be continued indefinitely for secondary stroke prevention after TIA or ischemic stroke, not for a limited duration. 1, 2
Duration of Antiplatelet Therapy
Daily long-term antiplatelet therapy should be prescribed immediately and continued indefinitely for secondary prevention of stroke and other vascular events in patients who have sustained a noncardioembolic TIA or ischemic stroke. 1, 2, 3 The evidence consistently supports continuous, lifelong therapy rather than time-limited treatment. 2, 4
Specific Agent Selection and Duration
First-Line Options (All Long-Term)
Clopidogrel 75 mg once daily is preferred over aspirin alone and should be continued indefinitely. 2, 3, 5
Aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily is equally preferred as first-line therapy and should be continued long-term. 1, 2, 3
Aspirin 75-100 mg daily remains an acceptable alternative if the preferred agents are not tolerated, continued indefinitely. 2, 3
Cilostazol Duration
Cilostazol 100 mg twice daily is an alternative antiplatelet agent but is less preferred than clopidogrel or aspirin/dipyridamole. 2, 5
When cilostazol is used, it should be continued long-term for secondary prevention. 5
Cilostazol reduced the risk of all strokes by 49% compared to placebo (OR 0.51,95% CI 0.37-0.71), though data are primarily from Asian populations. 5
Special Clinical Scenarios
Dual Antiplatelet Therapy (Time-Limited)
The only exception to indefinite monotherapy is short-term dual antiplatelet therapy for minor ischemic stroke or high-risk TIA:
Aspirin 81 mg daily plus clopidogrel 75 mg daily should be initiated within 12-24 hours of symptom onset. 4
This dual therapy is intended for short-term use only (typically 21-90 days), after which patients should transition to single antiplatelet therapy. 4, 3
Long-term combination of aspirin and clopidogrel is not recommended due to increased bleeding risk without additional benefit. 3, 6
Cardioembolic Stroke
For patients with atrial fibrillation who have had a cardioembolic TIA or stroke, oral anticoagulation (not antiplatelet therapy) is recommended indefinitely with target INR 2.0-3.0. 1, 7, 4
Aspirin 325 mg/day or clopidogrel 75 mg should only be used if oral anticoagulation cannot be administered, and this should be continued indefinitely. 1
Common Pitfalls to Avoid
Do not discontinue antiplatelet therapy after an arbitrary time period (e.g., 1 year, 5 years)—the recommendation is for lifelong therapy. 2
Do not delay initiation of antiplatelet therapy—it should be started immediately after TIA or ischemic stroke. 1, 2
Do not continue dual antiplatelet therapy (aspirin + clopidogrel) beyond the acute period (typically 21-90 days) as this increases bleeding risk without additional benefit. 3, 6
Do not use oral anticoagulation for noncardioembolic TIA/stroke unless there is a separate indication, as antiplatelet therapy is equally effective with lower bleeding risk. 1, 3